Question-and-Answer Session
Operator
(Operator Instructions). Quintin Lai of Robert W. Baird, you may ask your question.
Quintin Lai - Robert W. Baird
Hi, good morning. Happy New Year and congratulations on a nice quarter.
Nino De Chirico
Thank you, Quintin.
Quintin Lai - Robert W. Baird
This quarter was November fiscal end, could you talk a little bit about how business looked as you went into December? Any change in trends?
Nino De Chirico
No changes in trends. We keep seeing the same types of trends we saw in the six months before.
Quintin Lai - Robert W. Baird
So with respect to volumes and surgeries that require blood transfusion, you are not seeing any changes there?
Nino De Chirico
No, not on the reagent side like we said. The only effect we see now about this economic crisis is only in the capital purchases. Like we said in the beginning of the call, we see a less Galileo capital purchase we assume because of this crisis. We do not see any impact so far on the reagent sales.
Quintin Lai - Robert W. Baird
Have any of your customers that may have thought about Galileo, have they considered doing multiple Echo strategies?
Nino De Chirico
Yes. That is also another variable that we have. Some customers are also buying multiple Echo instead of a Galileo. However you know in Galileo there is another factor. We announced a new generation of Galileo and also we believe that maybe some customers can wait until the new generation is out, or we also had all the major high volume customer already equipped with Galileo. There are multiple factors.
Quintin Lai - Robert W. Baird
Thank you. Then can you give an update on the number of live Galileo's that you have now?
Nino De Chirico
Basically not live world wide we have only 14 Galileo at this point. There are a lot of instruments going live and in US I can give you more specific, we have total community orders 242 and live are 223.
Quintin Lai - Robert W. Baird
Thank you. Final question, I will jump back into the queue. The R&D number that you had for this quarter that takes into account a full quarter of BioArray. Is that a good run rate going forward or do you have any extra plans to maybe for accelerating some of the automation development within BioArray?
- To read the full transcript on Seeking Alpha, click here »
